BACKGROUND: It is well known that improving postoperative pain control in plastic surgery procedures leads to earlier mobilization, shortened hospital stay, reduced hospital costs, and increased patient satisfaction. OBJECTIVE: The authors evaluate the use of abdominal field block injections with liposomal bupivicaine (Exparel; Pacira Pharmaceuticals, Inc, San Diego, California) in postoperative pain management in patients undergoing abdominoplasty with rectus plication. METHODS: Case records from 64 female patients who underwent abdominoplasty with rectus plication were reviewed. We performed a total of 118 abdominoplasties with rectus plication, alone or in combination with other surgical procedures, from August 2012 to December 2012, but 54 patients were excluded from the series due to inadequate follow-up. Patients received liposomal bupivicaine injections in an abdominal field block fashion. Patient age, height, weight, and smoking status were recorded. Delivery of standardized postoperative intramuscular or intravenous injections and oral pain pills was recorded. Postoperative data and questionnaires were used to evaluate clinical efficacy. RESULTS: The average number of procedures (including abdominoplasty with rectus plication) per patient was 7. Average patient body mass index was 27 kg/m(2). Average pain scores were 3.5 (postoperative visit 1) and 2.8 (visit 2). The average number of oral pain pills required was 14 at the first postoperative visit and 11.5 at the second postoperative visit. Patients were able to resume normal activity at an average of 6.4 days. CONCLUSIONS: Our experience with liposomal bupivicaine injections for regional blocks in abdominoplasty with rectus plication indicates that patients experienced reduced postoperative pain, required less postoperative narcotic medication, and resumed both earlier ambulation and normal activity. Further investigation is warranted with more clinical cases to recommend the use of this medication for routine pain management after an abdominoplasty.
BACKGROUND: It is well known that improving postoperative pain control in plastic surgery procedures leads to earlier mobilization, shortened hospital stay, reduced hospital costs, and increased patient satisfaction. OBJECTIVE: The authors evaluate the use of abdominal field block injections with liposomal bupivicaine (Exparel; Pacira Pharmaceuticals, Inc, San Diego, California) in postoperative pain management in patients undergoing abdominoplasty with rectus plication. METHODS: Case records from 64 female patients who underwent abdominoplasty with rectus plication were reviewed. We performed a total of 118 abdominoplasties with rectus plication, alone or in combination with other surgical procedures, from August 2012 to December 2012, but 54 patients were excluded from the series due to inadequate follow-up. Patients received liposomal bupivicaine injections in an abdominal field block fashion. Patient age, height, weight, and smoking status were recorded. Delivery of standardized postoperative intramuscular or intravenous injections and oral pain pills was recorded. Postoperative data and questionnaires were used to evaluate clinical efficacy. RESULTS: The average number of procedures (including abdominoplasty with rectus plication) per patient was 7. Average patient body mass index was 27 kg/m(2). Average pain scores were 3.5 (postoperative visit 1) and 2.8 (visit 2). The average number of oral pain pills required was 14 at the first postoperative visit and 11.5 at the second postoperative visit. Patients were able to resume normal activity at an average of 6.4 days. CONCLUSIONS: Our experience with liposomal bupivicaine injections for regional blocks in abdominoplasty with rectus plication indicates that patients experienced reduced postoperative pain, required less postoperative narcotic medication, and resumed both earlier ambulation and normal activity. Further investigation is warranted with more clinical cases to recommend the use of this medication for routine pain management after an abdominoplasty.
Authors: Katelyn G Bennett; Brian P Kelley; Alexis D Vick; Jay S Lee; Vidhya Gunaseelan; Chad M Brummett; Jennifer F Waljee Journal: Plast Reconstr Surg Date: 2019-01 Impact factor: 4.730
Authors: Thomas W Hamilton; Vassilis Athanassoglou; Marialena Trivella; Louise H Strickland; Stephen Mellon; David Murray; Hemant G Pandit Journal: Cochrane Database Syst Rev Date: 2016-08-25
Authors: Daniel R Butz; Deana S Shenaq; Veronica L M Rundell; Brittany Kepler; Eric Liederbach; Jeff Thiel; Catherine Pesce; Glenn S Murphy; Mark Sisco; Michael A Howard Journal: Plast Reconstr Surg Glob Open Date: 2015-06-05
Authors: Brian D Terrien; David Espinoza; Charles C Stehman; Gabriel A Rodriguez; Nicholas C Connolly Journal: J Pain Res Date: 2017-01-16 Impact factor: 3.133
Authors: Neil Singla; Matthew Bindewald; Sonia Singla; David Leiman; Harold Minkowitz; Stewart W McCallum; Randall J Mack; Rosemary Keller; Alex Freyer; Wei Du Journal: Plast Reconstr Surg Glob Open Date: 2018-06-19
Authors: Nicole M King; Albin S Quiko; James G Slotto; Nicholas C Connolly; Robert J Hackworth; Justin W Heil Journal: J Pain Res Date: 2016-04-21 Impact factor: 3.133